Uncategorized
NovaBay reports third-quarter net loss of $5.2 million
NovaBay Pharmaceuticals reported a net loss of $5.2 million, or $0.07 per share, in the third quarter compared with a net loss of $4.2 million, or $0.08 per share, in the same period of 2014, according to a press release. The increase was attributed to higher spending on sales and marketing for Avenova and partially offset by less spending on research and development.